



**Program ASAS educational workshop Brussels  
October 12-13, 2015**

**Monday October 12, 8:30 – 12:30**

*Part 1. Concept of SpA, epidemiology, clinical features, diagnosis and criteria*

*Lecturers: Désirée van der Heijde, Robert Landewé*

8:30	Concept and epidemiology of SpA	<i>Désirée van der Heijde</i>
9:00	Imaging for the diagnosis of SpA	<i>Robert Landewé</i>
9:30	Diagnostic approach in patients with SpA	<i>Désirée van der Heijde</i>
10:00	<i>Coffee Break</i>	
10:30	ASAS classification criteria for SpA	<i>Robert Landewé</i>
11:00	Workshops (2 groups) Interpretation of imaging	<i>Désirée van der Heijde</i> <i>Robert Landewé</i>
12:00	Questions for the audience with voting	<i>Robert Landewé</i>
12:30	<i>Close</i>	

**Monday October 12, 13:30 – 17:30**

*Part 2. Outcome assessment including imaging*

*Lecturers: Joachim Sieper, Martin Rudwaleit*

13:30	Assessment of disease activity, function, QoL core sets, response and remission criteria, ASDAS	<i>Joachim Sieper</i>
	Imaging as outcome	<i>Martin Rudwaleit</i>
15:15	<i>Coffee</i>	
15:30	Workshops (2 groups) Spinal Mobility and assessments of radiographs	<i>Joachim Sieper</i> <i>Martin Rudwaleit</i>
17:00	Discussion workshops and voting	<i>Joachim Sieper</i> <i>Martin Rudwaleit</i>
17:30	<i>Close and dinner</i>	

## Tuesday October 13, 8:30 – 12:00

### Part 3. Pathophysiology, genetics, and extra-articular manifestations

Lecturers: Dirk Elewaut, Irene van der Horst

8:30	Pathophysiology of chronic inflammation in spondyloarthritis: from genes to cytokines	<i>Dirk Elewaut</i>
9:15	Inflammation and structural damage in spondyloarthritis: connected or not?	<i>Dirk Elewaut</i>
10:15	<i>Coffee Break</i>	
10:45	Extra-articular manifestations and SpA: Psoriasis, Inflammatory Bowel Disease, Uveitis	<i>Irene van der Horst</i>
12:00	<i>Close and lunch</i>	

## Tuesday October 13, 13:00 – 16:30

### Part 4. Management of SpA

Lecturers: Filip Van den Bosch, Percival Sampaio-Barros

13:00	Management of SpA	<i>Filip Van den Bosch</i>
13:30	Treatment of SpA - biologics	<i>Filip Van den Bosch</i>
14:00	Interactive clinical cases of SpA (2 groups)	<i>Percival Sampaio-Barros</i> <i>Filip Van den Bosch</i>
15:00	<i>Coffee</i>	
15:30	Examination with discussion and evaluation	<i>Percival Sampaio-Barros</i>
16:30	<i>Close and adjourn</i>	

## Expected Learning Outcomes

- To increase awareness of the full spectrum of spondyloarthritis diseases.
- To promote early and targeted referral to increase timely diagnosis in daily practice.
- To provide a practical approach to the use of classification criteria.
- To standardise the clinical examination of the axial disease manifestations.
- To improve interpretation of conventional x-ray and magnetic resonance imaging.
- To understand the pathogenetic mechanisms underlying spondyloarthritis.
- To consider the additional disease burden of extra-articular manifestations.
- To provide guidance on the current guidelines with regard to rational treatment.

## **Faculty ASAS educational workshop Brussels October 12-13, 2015**

### **Professor Robert Landewé,**

Robert Landewé is a professor in rheumatology at the Academic Medical Center / University of Amsterdam, The Netherlands, and a consultant in Rheumatology at the Atrium Medical Center Heerlen, The Netherlands.

Professor Landewé received his medical degree from Maastricht University in 1990, and defended his thesis on cyclosporine therapy in rheumatoid arthritis in 1994. He received practical training in general internal medicine and rheumatology at Atrium Medical Center, Heerlen and in rheumatology at the University Hospital, Maastricht.

Currently, Professor Landewé is involved in outcome research and epidemiological research in the field of rheumatoid arthritis and spondyloarthritis. He has extensive experience in the design and analysis of clinical trials and has a special interest in medical statistics. Professor Landewé has authored or co-authored more than 250 articles and many book chapters covering a variety of topics, but with an emphasis on clinical epidemiology, methodology, statistics and guideline development. He has led the EULAR recommendation initiatives on the management of early arthritis, the management of rheumatoid arthritis, and the measurement of disease activity in clinical trials. He is a regular reviewer for several general medicine, rheumatology and epidemiology journals.

Professor Landewé is executive committee member of Outcome Measures in Rheumatology Clinical Trials (OMERACT), president of the Assessment in Spondyloarthritis International Society (ASAS), and executive board member of the METEOR foundation (monitoring in rheumatology).

### **Professor Désirée van der Heijde**

Désirée van der Heijde is a Professor of Rheumatology in Leiden, the Netherlands, and is affiliated to the Diakonhjemmet Hospital, Oslo, Norway. She earned her medical degree at the Catholic University of Nijmegen, The Netherlands, in 1984. She performed clinical rheumatology research, including the development of the Disease Activity Score and the modified Sharp method, which led to her PhD degree. She has been a board-certified Rheumatologist since 1993.

Professor van der Heijde's major research interest is in outcomes assessment related to methodological aspects and their application in clinical studies. Specific areas of interest are methods for the radiographic scoring in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, as well as MRI scoring in ankylosing spondylitis.

Professor van der Heijde chaired the Assessment in SpondyloArthritis international Society (ASAS) between 1995 and 2012, and is a Chair of the EULAR Standing Committee of Clinical Affairs.

Professor van der Heijde has published more than 550 research papers in the international literature, as well as chapters in leading rheumatology textbooks. In 2011, she received the prestigious Carol-Nachman award for her scientific contributions to the field of rheumatology and in 2012 a doctorate honoris causa from the University of Ghent, Belgium.

### **Professor Joachim Sieper**

Prof Dr Joachim Sieper works as a rheumatologist at the Campus Benjamin Franklin of the Charité University Hospital in Berlin, Germany. He has a longstanding interest in the pathogenesis, epidemiology, diagnosis and treatment of spondyloarthritides with a focus on ankylosing spondylitis over the recent years. He was involved in several of the pivotal clinical studies showing the dramatic efficacy of TNF-blocking agents in the treatment of ankylosing spondylitis. He is recipient of the Carol-Nachman-Award for Rheumatology 2000 and of the EULAR-Award 2003. He is member of the editorial board of several international rheumatology journals. He has been an ASAS member for many years and was also in the past an active member of the ASAS executive committee over several years.

### **Professor Martin Rudwaleit**

Prof Dr Martin Rudwaleit is head of the Department of Internal Medicine and Rheumatology at Klinikum Bielefeld, Germany, is an academic teacher at Charité University Medicine in Berlin, Germany, and is guest professor at University of Gent, Belgium. Prof Rudwaleit is currently ASAS EC member and ASAS secretary. Prof Rudwaleit has been involved in clinical trials and in the research of ankylosing spondylitis and other spondyloarthritides, including epidemiology, clinical aspects, outcome assessments, imaging modalities, predictive parameters, classification and diagnosis of early disease. He has coordinated the German Spondyloarthritis Inception Cohort, a prospective longitudinal observational study on very early spondyloarthritis and has initiated and coordinated together with Prof. Sieper the international study on the development and validation of new ASAS classification criteria for axial SpA.

### **Professor Dirk Elewaut**

Dirk Elewaut is a full professor of rheumatology and immunology and Chair of the Department of Rheumatology at Ghent University Hospital, a EULAR and FOCIS center of excellence. He obtained his MD at Ghent University in 1991 and his PhD in 1997 at the same institution. Following postdoctoral research at the University of California San Diego and the La Jolla Institute for Allergy and Immunology he joined the faculty of the Department of Rheumatology at Ghent University Hospital in 2001. He has published more than 190 scientific publications, and is heading a team of 20 researchers of the Laboratory of Molecular Immunology and Inflammation at the same department. He is also a member of the editorial board of Arthritis Research and Therapy and Frontiers in Inflammation and has served as associate editor of Rheumatology and advisory editor of Arthritis & Rheumatism. His research interests are centered around translational aspects of immune regulation to combat inflammatory arthritis and associated joint damage, with special focus on the link between gut and joint inflammation in spondyloarthritis.

### **Professor Irene van der Horst-Bruinsma**

Irene van der Horst-Bruinsma is an Associate Professor of Rheumatology at the VU university Medical Centre in Amsterdam, The Netherlands since 1998, head of the Centre of Excellence on Spondyloarthritis at the same institution (which is also a

EULAR centre of excellence) and vice-president of the Medical Faculty of this hospital. She earned her medical degree in 1987 at the University of Leiden, The Netherlands. After her training at the Leiden University Medical Centre she was certified as a rheumatologist in 1997 and earned her PhD degree on the role of HLA-antigens in Rheumatoid Arthritis in 1998.

Associate Professor van der Horst-Bruinsma's major research interest is in Spondyloarthritis, focussed on new treatment options in very early stages of the disease, clinical outcome, gender differences, co-morbidity and extra-articular manifestations, such as uveitis and performs research in genetics in Spondyloarthritis. She has published more than 140 articles or book chapters in rheumatology textbooks, including the EULAR on line course on Medical treatment of Spondyloarthritis. She was president of the Executive Board of the Netherlands Rheumatoid Arthritis Surgical Society (NERASS) and chaired the committee of national guidelines on Diagnosis and Treatment of Axial Spondyloarthritis of the Dutch Society of Rheumatology.

Associate Professor van der Horst-Bruinsma is executive committee member of the Assessment of Spondyloarthritis International Society (ASAS) and member of the steering committee of the International Genome wide Association studies in AS (IGAS).

### **Professor Filip Van den Bosch**

Filip Van den Bosch graduated in medicine at the University of Ghent, Belgium in 1991; he became board certified in rheumatology in 1996 and received a PhD degree in 2003, with his doctoral thesis focusing on the exploration of the therapeutic potential of TNF-alpha blockade in spondyloarthritis patients and more specifically in patients with bowel related arthritis.

He is currently working as Head-of-Clinic and associate professor of Rheumatology in the Department of Rheumatology at the University Hospital of Ghent University. He also has the final responsibility for the rheumatologists in training at the University Hospital. The department has a long history of performing clinical and basic research, linking inflammatory bowel disease to the different rheumatological entities belonging to the spondyloarthritis concept. The department has been cited continuously as a Centre of Excellence in Rheumatology by EULAR since 2006.

He currently serves as the treasurer of the 'Assessments in SpondyloArthritis International Society' (ASAS); he is also member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). His main interests are in clinical research. Dr. Van den Bosch has been an investigator in several international or investigator-initiated clinical trials and mechanism-of-action studies in the areas of rheumatoid arthritis, osteoarthritis and especially the diseases belonging to the spondyloarthritis concept. He is the author or co-author of more than 90 peer-reviewed international publications and chapters in textbooks.

## **Professor Percival Sampaio-Barros**

Dr. Percival Sampaio-Barros graduated from the University of Campinas in 1986, where he specialized in Rheumatology (1987-1989) and became a Doctor in Internal Medicine (1993). Since 2009, Dr. Sampaio-Barros is Assistant Rheumatologist in the Division of Rheumatology at the University of São Paulo School of Medicine (FM – USP).

He was President of the Committee of Spondyloarthritis of the Brazilian Society of Rheumatology (2006-2012), and is the National Coordinator of the Brazilian Registry of Spondyloarthritis (RBE) since 2006. Dr. Sampaio-Barros was the general coordinator of the First Brazilian Guidelines of Treatment of Ankylosing Spondylitis and Psoriatic Arthritis (2004), and also coordinated the First (2007) and Second Update (2012) of these Guidelines. He is also member of ASAS (where he became a member of the Executive Committee in 2014), and GRAPPA.

Dr. Sampaio-Barros was also the Coordinator of the Committee of Systemic Sclerosis of the Brazilian Society of Rheumatology (2010-2014), and of the Panamerican League of Associations of Rheumatology (PANLAR) (2008-2014). He is also President of the Scientific Board of the Brazilian Association of Patients with Systemic Sclerosis (ABRAPES) and also member of the Scientific Board of the Brazilian Association of Rheumatic Patients (ANAPAR). Dr. Sampaio-Barros received the award of “Distinguished Member of PANLAR” in 2008.

In addition to these roles, Dr. Sampaio-Barros has also been a reviewer and member of the editorial board for many publications in the field of Rheumatology. He has published over 100 papers, with research interests in ankylosing spondylitis, systemic scleroderma and psoriatic arthritis.